ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Kaempferol: advances in biosynthesis, molecular mechanisms, and therapeutic applications.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kaempferol is a ubiquitous dietary flavonol found in fruits, vegetables, and medicinal plants, existing in both aglycone and glycosylated forms which contribute to its structural and functional diversity. This review provides a comprehensive overview of kaempferol, focusing on its biosynthesis, pharmacokinetic challenges, and the mechanistic basis for its diverse pharmacological properties. Its biosynthesis originates from phenylalanine, with subsequent enzymatic modifications yielding derivatives of varying bioactivity. The principal mechanism of kaempferol is rooted in its potent antioxidant capacity, acting through both direct radical scavenging and the upregulation of the cytoprotective Nrf2 pathway. This redox modulation is intricately linked to its anti-inflammatory effects, which are mediated by the suppression of key signaling cascades including NF-κB, MAPKs, and STATs. In preclinical models, kaempferol demonstrates significant antidiabetic activity by activating AMPK and enhancing insulin sensitivity. Its anticancer properties are equally notable, involving the induction of apoptosis, cell cycle arrest, and inhibition of metastasis through the disruption of pathways such as PI3K/AKT and Wnt/β-catenin. Furthermore, it exhibits antimicrobial effects and hepatoprotective actions by modulating SIRT1/AMPK signaling. Despite these promising bioactivities, therapeutic translation is severely hampered by its poor aqueous solubility and extensive first-pass metabolism, which critically limit oral bioavailability. Consequently, while kaempferol is a compelling polypharmacological agent with the potential to address complex diseases, its unfavorable pharmacokinetic profile remains the critical bottleneck for clinical advancement. A promising direction for future research is to prioritize the development of advanced drug delivery systems and the execution of rigorous clinical trials to translate its extensive preclinical promise into validated clinical applications.
Indexed as
Identifiers
42287316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.